These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

284 related items for PubMed ID: 29851356

  • 1. Effect of tetrahydrocannabinol:cannabidiol oromucosal spray on activities of daily living in multiple sclerosis patients with resistant spasticity: a retrospective, observational study.
    Mallada Frechín J.
    Neurodegener Dis Manag; 2018 Jun; 8(3):151-159. PubMed ID: 29851356
    [Abstract] [Full Text] [Related]

  • 2. Tetrahydrocannabinol:Cannabidiol Oromucosal Spray for Multiple Sclerosis-Related Resistant Spasticity in Daily Practice.
    Vermersch P, Trojano M.
    Eur Neurol; 2016 Jun; 76(5-6):216-226. PubMed ID: 27732980
    [Abstract] [Full Text] [Related]

  • 3. Tetrahydrocannabinol and cannabidiol oromucosal spray in resistant multiple sclerosis spasticity: consistency of response across subgroups from the SAVANT randomized clinical trial.
    Meuth SG, Henze T, Essner U, Trompke C, Vila Silván C.
    Int J Neurosci; 2020 Dec; 130(12):1199-1205. PubMed ID: 32065006
    [Abstract] [Full Text] [Related]

  • 4. Newest evidence for tetrahydrocannabinol:cannabidiol oromucosal spray from postapproval pragmatic studies.
    Patti F.
    Neurodegener Dis Manag; 2019 Apr; 9(2s):3-7. PubMed ID: 30657027
    [Abstract] [Full Text] [Related]

  • 5. Tetrahydrocannabinol/Cannabidiol Oromucosal Spray in Patients With Multiple Sclerosis: A Pilot Study on the Plasma Concentration-Effect Relationship.
    Contin M, Mancinelli L, Perrone A, Sabattini L, Mohamed S, Scandellari C, Foschi M, Vacchiano V, Lugaresi A, Riva R.
    Clin Neuropharmacol; 2018 Apr; 41(5):171-176. PubMed ID: 30024443
    [Abstract] [Full Text] [Related]

  • 6. Influence of Previous Failed Antispasticity Therapy on the Efficacy and Tolerability of THC:CBD Oromucosal Spray for Multiple Sclerosis Spasticity.
    Haupts M, Vila C, Jonas A, Witte K, Álvarez-Ossorio L.
    Eur Neurol; 2016 Apr; 75(5-6):236-43. PubMed ID: 27160412
    [Abstract] [Full Text] [Related]

  • 7. The influence of THC:CBD oromucosal spray on driving ability in patients with multiple sclerosis-related spasticity.
    Celius EG, Vila C.
    Brain Behav; 2018 May; 8(5):e00962. PubMed ID: 29761015
    [Abstract] [Full Text] [Related]

  • 8. Palatability and oral cavity tolerability of THC:CBD oromucosal spray and possible improvement measures in multiple sclerosis patients with resistant spasticity: a pilot study.
    Lus G, Cantello R, Danni MC, Rini A, Sarchielli P, Tassinari T, Signoriello E.
    Neurodegener Dis Manag; 2018 Apr; 8(2):105-113. PubMed ID: 29683408
    [Abstract] [Full Text] [Related]

  • 9. A review of the effects of baclofen and of THC:CBD oromucosal spray on spasticity-related walking impairment in multiple sclerosis.
    Arroyo González R.
    Expert Rev Neurother; 2018 Oct; 18(10):785-791. PubMed ID: 30235965
    [Abstract] [Full Text] [Related]

  • 10. Clinical experience with THC:CBD oromucosal spray in patients with multiple sclerosis-related spasticity.
    Koehler J, Feneberg W, Meier M, Pöllmann W.
    Int J Neurosci; 2014 Sep; 124(9):652-6. PubMed ID: 24392812
    [Abstract] [Full Text] [Related]

  • 11. Application device for THC:CBD oromucosal spray in the management of resistant spasticity: pre-production testing.
    Montero-Escribano P, Vila Silván C.
    Expert Rev Med Devices; 2019 Sep; 16(9):835-840. PubMed ID: 31393179
    [Abstract] [Full Text] [Related]

  • 12. Long-Term Data of Efficacy, Safety, and Tolerability in a Real-Life Setting of THC/CBD Oromucosal Spray-Treated Multiple Sclerosis Patients.
    Paolicelli D, Direnzo V, Manni A, D'Onghia M, Tortorella C, Zoccolella S, Di Lecce V, Iaffaldano A, Trojano M.
    J Clin Pharmacol; 2016 Jul; 56(7):845-51. PubMed ID: 26608223
    [Abstract] [Full Text] [Related]

  • 13. Tetrahydrocannabinol: cannabidiol oromucosal spray for treating symptoms of multiple sclerosis spasticity: newest evidence.
    Ziemssen T.
    Neurodegener Dis Manag; 2019 Apr; 9(2s):1-2. PubMed ID: 30657019
    [Abstract] [Full Text] [Related]

  • 14. Newest evidence for tetrahydrocannabinol:cannabidiol oromucosal spray from randomized clinical trials.
    Marková J.
    Neurodegener Dis Manag; 2019 Apr; 9(2s):9-13. PubMed ID: 30657024
    [Abstract] [Full Text] [Related]

  • 15. THC:CBD in Daily Practice: Available Data from UK, Germany and Spain.
    Fernández Ó.
    Eur Neurol; 2016 Apr; 75 Suppl 1():1-3. PubMed ID: 26901342
    [Abstract] [Full Text] [Related]

  • 16. Effectiveness and Tolerability of THC/CBD Oromucosal Spray for Multiple Sclerosis Spasticity in Italy: First Data from a Large Observational Study.
    Trojano M, Vila C.
    Eur Neurol; 2015 Apr; 74(3-4):178-85. PubMed ID: 26571097
    [Abstract] [Full Text] [Related]

  • 17. Sativex® as add-on therapy vs. further optimized first-line ANTispastics (SAVANT) in resistant multiple sclerosis spasticity: a double-blind, placebo-controlled randomised clinical trial.
    Markovà J, Essner U, Akmaz B, Marinelli M, Trompke C, Lentschat A, Vila C.
    Int J Neurosci; 2019 Feb; 129(2):119-128. PubMed ID: 29792372
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.